115 related articles for article (PubMed ID: 19197721)
21. A novel clinicogenetic prognostic score for follicular lymphoma.
López-Guillermo A
Lancet Oncol; 2015 Sep; 16(9):1011-1012. PubMed ID: 26256759
[No Abstract] [Full Text] [Related]
22. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V
Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580
[TBL] [Abstract][Full Text] [Related]
23. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
Hagenbeek A
Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512
[No Abstract] [Full Text] [Related]
24. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
25. Towards a chemotherapy-free approach in indolent lymphoma.
Buske C
Lancet Oncol; 2014 Nov; 15(12):1281-2. PubMed ID: 25439681
[No Abstract] [Full Text] [Related]
26. Is there a role for autotransplants in patients with follicular lymphoma in the rituximab era?
Armitage JO
Transfus Apher Sci; 2013 Aug; 49(1):24-6. PubMed ID: 23850133
[TBL] [Abstract][Full Text] [Related]
27. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.
Hilchey SP; Hyrien O; Mosmann TR; Livingstone AM; Friedberg JW; Young F; Fisher RI; Kelleher RJ; Bankert RB; Bernstein SH
Blood; 2009 Apr; 113(16):3809-12. PubMed ID: 19196657
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
Dang NH; Fayad L; McLaughlin P; Romaguara JE; Hagemeister F; Goy A; Neelapu S; Samaniego F; Walker PL; Wang M; Rodriguez MA; Tong AT; Pro B
Br J Haematol; 2007 Aug; 138(4):502-5. PubMed ID: 17608763
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
30. Rituximab combined with a small dose of melphalan for a refractory follicular lymphoma patient.
Saigo K; Okumachi Y; Kondo S; Chinzei T; Okamura A; Takenokuchi M; Kawano S; Kumagai S
Leuk Lymphoma; 2006 Feb; 47(2):353-6. PubMed ID: 16321871
[TBL] [Abstract][Full Text] [Related]
31. Rituximab maintenance for follicular lymphoma.
Vidal L; Gafter-Gvili A; Shpilberg O
Nat Rev Clin Oncol; 2010 Mar; 7(3):1; author reply 1. PubMed ID: 20222179
[No Abstract] [Full Text] [Related]
32. Patient benefits of maintenance immunotherapy.
Ghielmini M
Leuk Res; 2006 Mar; 30 Suppl 1():S22-6. PubMed ID: 16750675
[TBL] [Abstract][Full Text] [Related]
33. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
34. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
[TBL] [Abstract][Full Text] [Related]
36. Primary follicular lymphoma of the small intestine.
Chim CS; Loong F; Leung AY; Tsang J; Ooi GC
Leuk Lymphoma; 2004 Jul; 45(7):1463-6. PubMed ID: 15359649
[TBL] [Abstract][Full Text] [Related]
37. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
38. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
40. Novel antibodies against follicular non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Best Pract Res Clin Haematol; 2011 Jun; 24(2):231-56. PubMed ID: 21658621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
